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Abstract
Background: The precise regulation and maintenance of balance between cell proliferation, differentiation and death in
metazoan are critical for tissue homeostasis. CCAAT/enhancer-binding protein alpha (C/EBPa) has been implicated as a key
regulator of differentiation and proliferation in various cell types. Here we investigated the potential dynamic change and
role of C/EBPa protein during apoptosis induction.
Methodology/Principal Findings: Upon onset of apoptosis induced by various kinds of inducers such as NSC606985,
etoposide and others, C/EBPa expression presented a profound down-regulation in leukemic cell lines and primary cells via
induction of protein degradation and inhibition of transcription, as assessed respectively by cycloheximide inhibition test,
real-time quantitative RT-PCR and luciferase reporter assay. Applying chemical inhibition, forced expression of dominant
negative mutant and catalytic fragment (CF) of protein kinase Cdelta (PKCd), which was proteolytically activated during
apoptosis induction tested, we showed that the active PKCd protein contributed to the increased degradation of C/EBPa
protein. Three specific proteasome inhibitors antagonized C/EBPa degradation during apoptosis induction. More
importantly, ectopic expression of PKCd-CF stimulated the ubiquitination of C/EBPa protein, while the chemical inhibition
of PKCd action significantly inhibited the enhanced ubiquitination of C/EBPa protein under NSC606985 treatment.
Additionally, silencing of C/EBPa expression by small interfering RNAs enhanced, while inducible expression of C/EBPa
inhibited NSC606985/etoposide-induced apoptosis in leukemic cells.
Conclusions/Significance: These observations indicate that the activation of PKCd upon apoptosis results in the increased
proteasome-dependent degradation of C/EBPa, which partially contributes to PKCd-mediated apoptosis.
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Introduction
The precise regulation and maintenance of balance between cell
proliferation, differentiation and death in multicellular organisms
are critical for tissue homeostasis. Their disorders would cause the
pathogenesis of many diseases, especially cancers including
leukemias. Increasing lines of evidence support that the same
proteincanexertsomerolesinallorsomeoftheseimportantcellular
events. For example, several caspases involved in cell apoptosis were
shown to play a role in the differentiation of erythroid cells and
macrophages [1]. Anti-apoptotic Bcl-2 is also associated with stem
cells-committed differentiation and morphogenesis [2].
CCAAT/enhancer-binding protein alpha (C/EBPa), of which
the genetic nomenclature is dubbed CEBPA, has been implicated
as a key regulator of differentiation in various cell types such as
adipocytes, hepatocytes and myeloid cells [3–5]. Its mutations
were also found in about 10% of acute myeloid leukemia (AML)
[6], and inhibition of its expression or function is also blocked by
leukemogenesis-related genetic alterations such as t(8;21)-generat-
ed AML1-ETO [7–9] or t(9;22)-generated BCR-ABL fusion
protein [10]. More recently, C/EBPa was also reported to induce
the expression of anti-apoptotic Bcl-2 gene in hematopoietic cell
lines in a manner independent of its DNA binding activity and
protects Ba/F3 (a widely studied immature murine hematopoietic
cell line with a pro-B lymphoid phenotype) from apoptosis on
interleukin-3 withdrawal [11]. In this work, we investigate whether
C/EBPa expression is modulated during apoptosis and whether
C/EBPa contributes to apoptosis development in a common
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6552sense. Our observations indicate that the activation of protein
kinase Cdelta (PKCd) upon apoptosis results in the increased
proteasome-dependent degradation of C/EBPa, which partially
contributes to PKCd-mediated apoptosis.
Results
C/EBPa protein is significantly reduced upon apoptosis
induction in leukemic cells
To evaluate whether the C/EBPa protein is regulated during
apoptosis induction, NSC606985 (a water-soluble camptothecin
ester derivative [12,13]) was used as an apoptosis-inducing agent.
Consistent with our previous report [14], the proteolytic activation
of caspase-3 (a critical apoptosis effector [15]), as assessed by
decreased pro-caspase-3 and increased active fragments of
caspase-3, was induced by 25 nM of NSC606985 treatment for
12 hours in acute promyelocytic leukemic (APL) NB4 cells or by
50 nM of NSC606985 treatment for 36 hours in acute monocytic
leukemic U937 cells (Figure 1A). Concomitantly, the treatment
also triggered these two cell lines to undergo apoptosis, in which
NB4 cells were more sensitive than U937 cells, as estimated by
percentages of annexin-V
+ cells and sub-G1 cells on flow
cytometry as well as the Wright’s staining-based morphological
examinations (Figure S1). When the activated caspase-3 was
detected, more intriguingly, C/EBPa protein was significantly
reduced to an undetectable level in NSC606985-treated NB4 and
U937 cells (Figure 1A). Of note, only the p42 isoform of C/EBPa
could be clearly detected in NB4 and U937 cells, although there
are two C/EBPa isoforms (p42 and p30) [16]. Therefore, C/EBPa
protein is its p42 isoform in the following experiments.
Additionally, 50 nM of NSC606985 also effectively reduced C/
EBPa protein together with the cleaved activation of PKCd
(Figure 1B) and apoptosis induction (data not shown) in primary
leukemic cells from bone marrow (BM) of two AML patients. To
determine whether the reduced C/EBPa protein is NSC606985-
specific or apoptosis-dependent, other apoptosis inducers including
etoposide, doxorubicin, arsenic trioxide (As2O3) and ultraviolent
(UV) radiation were applied to NB4 and U937 cells. All these
insults could effectively induce apoptosis of these two cell lines
(Figure S2/S3) together with proteolytic activation of caspase-3
(Figure 1C/D). Meanwhile, C/EBPa protein was also reduced in
NB4 and U937 cells (Figure 1C/D). Notably, C/EBPb and p53
proteins were undetectable in NB4 and U937 cells, respectively,
and both NSC606985 and etoposide failed to alter the expression
of C/EBPb protein in U937 cells or p53 protein in NB4 cells
(Figure 1A/C). All these data supported that the reduction of C/
EBPa protein is common to apoptosis induction.
Both inhibition of transcription and induction of protein
degradation contribute to the down-regulation of C/
EBPa expression during apoptosis
To test whether C/EBPa expression is regulated at the post-
transcriptional level during apoptosis, NB4 cells were treated with
10 mg/ml cycloheximide (CHX) and/or NSC606985 or etoposide
for the different times. As shown in Figure 2A, half-life of C/EBPa
protein in NB4 cells was more than 8 hours. In NSC606985 or
Figure 1. C/EBPa protein is significantly reduced upon the onset of apoptosis in leukemic cells. NB4 and U937 cells were treated
respectively with 25 nM and 50 nM of NSC606985 (A) or 0.5 mM and 1 mM etoposide (C). Fresh leukemic cells were treated with 50 nM NSC606985
(B), or NB4 cells were treated with 2 mMA s 2O3, 0.5 mM doxorubicin or irradiated by 150J UV for hours as indicated (D). The indicated proteins were
detected by Western blots with b-actin as an internal control. Dcaspase-3 and DPKCd indicate activated fragments of caspase-3 and cleaved 41kDa
catalytic fragment of PKCd, respectively. Each experiment was repeated three times with similar results. Fold changes (means6SD from three
independent tests) for C/EBPa/b-actin against untreated cells are shown on the bottom of panels A and B. Symbol * represents P value of less than
0.01 compared with the untreated (0 hour) cells.
doi:10.1371/journal.pone.0006552.g001
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decreased to less than 50% at 4 hours after CHX blockage of
protein synthesis, indicating that the stabilization of the C/EBPa
protein was also lowered upon apoptosis induction. Evan so, we
continued to dynamically measure the mRNA level of CEBPA in
NSC606985- or etoposide-treated NB4 and U937 cells by real-
time quantitative RT-PCR. The results revealed that
NSC606985/etoposide-treated NB4 cells also presented reduced
CEBPA mRNA, which initially appeared at 6 hours and 24 hours
after treatment of NSC606985 and etoposide respectively, and
became more significant later (Figure 2B). The reduced CEBPA
mRNA could also be seen in NSC606985/etoposide-treated U937
cells, but CEBPA mRNA also experienced a rapid but temporary
increase before the down-regulation in U937 cells (Figure 2B).
This was also true for C/EBPa protein in U937 but not in NB4
cells treated by both NSC606985 and etoposide, although statistic
significance was absent (Figure 1A/B). Furthermore, a CEBPA
promoter-driven luciferase reporter assay also supported
NSC606985 and etoposide significantly inhibited CEBPA gene
promoter-driven luciferase transcription in both NB4 and U937
cells (Figure 2C). It should be point out that although the
transitory elevation of CEBPA gene promoter-driven transcription
could also be tested in U937 cells under the treatment of
NSC606985 or etoposide, the early elevation of the reporter gene
is very weak which indicated that there may be other mechanisms
involved in the transient elevation of CEBPA mRNA. All these
results proposed that both reduced transcription and increased
degradation contributed to the down-regulation of C/EBPa
expression during apoptosis induction.
The proteolytically activated PKCd is critical for the
enhanced protein degradation of C/EBPa during
apoptosis
It has been known that PKCd, a novel member of the PKC
family, is implicated as an important regulator of apoptotic
responses, especially in DNA-damaging agents-induced apoptosis
[14,17,18]. The proteolytic activation of PKCd, which results in the
generation of an active kinase domain [19], occurs in response to a
variety of stimuli including DNA-damaging agents and exerts a
crucial role in NSC606985/etoposide-induced apoptosis [9,14,20].
In line with our previous reports [14,21], NSC606985/etoposide
induced a proteolytic cleavage of PKCd into a 41kDa catalytic
fragment (Figure 1A-C) that persistently activated the kinase [20].
Of note, the PKCd antibody also detected a strong band between
the full-length PKCd and the catalytic fragment (CF) of PKCd,
which also disappeared when cells are treated with apoptotic
stimuli. What this band actually corresponds to remained to be
explored. Also, it should be pointed out that the increase of
truncated PKCd had a good correlation with the decrease of full-
length PKCd after 24 hours of NSC606985 treatment in NB4 cells,
but such correlation was not so remarkable in NSC606985 or
etoposide-treated U937 cells. We extrapolated that this might be
due to higher sensitivity of NB4 cells than U937 cells to etoposide
and especially NSC606985-induced apoptosis (Figure S1/S2). The
proteolytic activation of PKCd was also present in UV, doxorubicin
and As2O3-induced apoptosis (Figure 1D). Considering that the
proteolytic activated PKCd protein could target some proteins for
their degradation [22] and the PKCd activation also occurred
before the reduced C/EBPa protein according to time-course
analysis (Figure 1A/C and ref [14]), we extrapolated that the PKCd
activation was related to the degradation of C/EBPa protein.
Hence, U937 and NB4 cells were pretreated withthe specific PKCd
inhibitor rottlerin, which significantly inhibited NSC606985-
induced proteolytic activation of PKCd (Figure 3A). Likewise, it
also antagonized activation of caspase-3, cleavage of its substrate
poly-ADP ribose polymerase (PARP) (Figure 3A) and apoptosis
(Figure 3B) induced by NSC606985. In parallel, rottlerin also
partially restored C/EBPa protein but not its mRNA level upon
NSC606985 treatment in both cells (Figure 3A).
Since rottlerin directly uncouples mitochondrial respiration from
oxidative phosphorylation, and could block any number of ATP-
dependent processes or inhibit other kinases [23,24], data using
rottlerin should be evaluated cautiously. Therefore, we also tested
the effect of a dominant-negative mutant of PKCd (DN-PKCd),
which selectively inhibits action of PKCd [25] and blocks apoptosis
in response to diverse apoptotic stimuli [26]. By a retrovirus-
infecting system, U937 cell line with stable transfection of the Flag-
tagged DN-PKCd (U937
Flag-DN-PKCd) or its control vector (U937
ve-
hicle) wasgenerated.Ourresults showedthat theforcedexpression of
Flag-DN-PKCd significantly antagonized NSC606985–induced the
activations of caspase-3 and PKCd (Figure 3C) and apoptosis
induction (Figure 3D) in U937
Flag-DN-PKCd cells. Accordingly, DN-
PKCd expression also antagonized the decrease of C/EBPa protein
(Figure 3C) but not its mRNA level (Figure S4).
Furthermore, pTRE2hyg-PKCd-CF-expressing vector and
empty vector pTRE2hyg were respectively stably transfected to
U937T cells, which contain stably transfected pUHD-tTA
(tetracycline responsive transcription activator), whose expression
is under the control of tetracycline [27]. Here, these transfected
cells were referred as the U937
PKCd-CF and U937
mock cells,
respectively. In U937
PKCd-CF cells but not U937
mock cells, PKCd-
CF protein was induced significantly with no alteration of
endogenous full-length PKCd protein from day 2 after tetracycline
removal (Figure 3E). In this case, caspase-3 was also activated
(Figure 3E) with apoptosis induction (Figure 3F). More intrigu-
ingly, the expression of PKCd-CF also reduced C/EBPa protein
but not its mRNA in U937
PKCd-CF cells. All these observations
strongly suggested that proteolytic activated PKCd contributed to
the enhanced degradation of C/EBPa protein during apoptosis.
Activated caspase-3 fails to induce the degradation of C/
EBPa protein
Considering that all five apoptosis insults used here (Figure 1)
and the inducible expression of PKCd-CF (Figure 3E) could
activate caspase-3 and that inhibition of PKCd activation by
rottlerin and DN-PKCd expression abrogated caspase-3 activation
(Figure 3A/C), we asked whether PKCd mediates degradation of
C/EBPa protein via activated caspase-3, which is an important
member of a unique caspase family of conserved cysteine proteases
that cleaves an impressive array of substrates after an aspartate
residue [28]. As reported before [14], the pretreatment of cell-
permeable caspase-3 inhibitor Z-DEVD-fmk almost completely
blocked caspase-3 activation, which in turn partially inhibited
proteolytic cleavage of PKCd (Figure 4A) and it also partially
blocked apoptosis induced by NSC606985 (data not shown).
However, this inhibitor failed to rescue NSC606985-reduced C/
EBPa protein (Figure 4A). By the way, the purified recombinant
his-tagged active fragment of caspase-3 could cleave AML1-ETO
protein as described [29,30], but it did not destroy the GST-C/
EBPa protein (Figure 4B). All these experiments indicated that
activated caspase-3 does not contribute to the degradation of C/
EBPa protein during apoptosis.
Proteasome inhibitors antagonize increased degradation
of C/EBPa protein during apoptosis
Since C/EBPa protein can be degraded via the ubiquitin-
proteasomal system [31], we continued to explore the possible
PKCd and C/EBPa Degradation
PLoS ONE | www.plosone.org 3 August 2009 | Volume 4 | Issue 8 | e6552Figure 2. The decrease of C/EBPa protein during apoptosis involves induction of protein degradation and inhibition of
transcription. (A) After pretreatment with 25 nM of NSC606985 or 0.5 mM of etoposide for 12 hours, NB4 cells were incubated with 10 mg/ml CHX
for indicated hours. Then, C/EBPa protein was detected with b-actin as a loading control. Folds of decrease of C/EBPa protein/b-actin ratios against
untreated cells are shown as means6SD of three independent experiments. (B) NB4 (top) and U937 cells(bottom) were treated respectively with
25 nM and 50 nM of NSC606985 (left) or 0.5 mM and 1 mM etoposide (right) for hours as indicated, and CEBPA mRNA level was detected by real-time
quantitative RT-PCR. (C) NB4 (top) and U937 cells (bottom) were transfected with CEBPA promotor-luciferase plasmid together with pRL-SV40 vector.
After 24 hours of transfection, these cells were treated respectively with 25 nM and 50 nM of NSC606985 (left) or 0.5 mM and 1 mM etoposide (right)
for hours as indicated. Then, the cells were harvested and the relative luciferase activities were measured. The columns represent means of fold
changes against untreated cells, with the bar as S.D. of three independent experiments each with triplicates The symbol * indicates P value compared
with untreated cells.
doi:10.1371/journal.pone.0006552.g002
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tion. For this purpose, three specific proteasome inhibitors
including epoxomicin [32], bortezomib [33] and MG-132 [34]
were each used to treat U937 cells together with 50 nM of
NSC606985. The results showed that all three inhibitors,
especially epoxomicin and bortezomib, significantly antagonized
Figure 3. The proteolytically activated PKCd is critical for the enhanced C/EBPa degradation during apoptosis. (A-B) After
pretreatment for 2 hours in the presence or absence of 2 mM and 1 mM of rottlerin respectively for U937 and NB4 cells, U937 cells were treated with
or without 50 nM of NSC606985 for an additional 36 hours or NB4 cells were treated with or without 25 nM of NSC606985 for an additional 18 hours.
Then, the indicated proteins (top panel, A), relative CEBPA mRNA (bottom panel, A), and annexin-V
+ cells% (B) were tested. (C-D) U937
Flag-DN-PKCd and
U937
vehicle cells were treated with 50 nM NSC606985 for 36 hours. Then, the indicated proteins (C) and annexin-V
+ cells%(D) were measured. (E)
U937
mock and U937
PKCd-CF cells were incubated for the indicated days after tetracycline withdrawal, and the indicated proteins (top panel) and
relative CEBPA mRNA (bottom panel) were determined. (F) U937
mock and U937
PKCd -CF cells were incubated in medium with (+) or without (2)
tetracycline for 4 days, and annexin-V
+ cells% were measured on flow cytometry. Here, Dcaspase-3, DPKCd and DPARP indicate activated fragments
of caspase-3, cleaved 41kDa catalytic fragments of PKCd and cleaved fragments of PARP, respectively. In panel C, Flag-DN-PKCd was detected by anti-
Flag antibody, and the symbol * indicated a non-corresponding band. In panel A/E, the columns represent means of change folds of CEBPA mRNA
against untreated cells, with the bar as S.D. of three independent experiments with triplicates each. In panel B, D and F, the values represent annexin
V
+ cells with and without PI staining, as expressed by mean6S.D. of three independent experiments each with triplicates, and the symbol *
represents P,0.01 compared with NSC606985 treatment alone (B), U937
vehicle cells (D) or U937
mock cells with the corresponding treatment.
doi:10.1371/journal.pone.0006552.g003
Figure 4. Caspase-3 dose not degrade C/EBPa protein. (A) After pre-incubation with 40 mM Z-DEVD-fmk for 1 hour, NB4 cells were treated
with or without 25 nM NSC606985 for an additional 18 hours. Then, the indicated proteins were detected by Western blots. Dcaspase-3 and DPKCd
indicate activated fragments of caspase-3 and cleaved catalytic fragment of PKCd, respectively. (B) Bacteria expressing GST-C/EBPa or GST-AML1-ETO
were incubated with or without recombinant his-tagged active fragment of caspase-3 at 25uC for 3 hours. The mixtures were blotted with anti-C/
EBPa, ETO and/or activated capase-3 antibodies. ‘‘D’’ points to a cleaved fragment of AML1-ETO protein.
doi:10.1371/journal.pone.0006552.g004
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MG132 and bortezomib at concentration used also induced
and/or enhanced NSC606985-induced PKCd and caspase-3
activation (Figure 5A) and cell death (Figure S5) due to their
potential cell toxicities widely documented [35]. Furthermore,
MG132 also inhibited degradation of C/EBPa protein in the
presence of CHX in NSC606985/etopsoside-treated or untreated
NB4 cells (Figure 5B). These results suggested that the proteasomal
mechanism contributes to the enhanced degradation of C/EBPa
protein upon apoptosis.
The activated PKCd possibly mediates the enhanced
ubiquitination of C/EBPa protein during apoptosis
induction
Next we tested whether NSC606985 induces the ubiquitination
of C/EBPa protein. To do this, NB4 cells were treated with or
without 25 nM of NSC606985 and/or proteosome inhibitor
MG132 for 12 hours, at which point PKCd was activated without
decrease of C/EBPa protein (Figure 1A/6A), and C/EBPa
protein was immunoprecipitated followed by western blot with
antibody against ubiquitin. As shown in Figure 6A, MG132
treatment effectively increased the ubiquitinated C/EBPa protein
which could not be detected in untreated cells, indicating the
specificity and effectiveness of the assay system. NSC606985
treatment also significantly increased the ubiquitinated C/EBPa
protein regardless of the presence of MG132. More intriguingly,
when the activation of PKCd was blocked by rottlerin, as shown in
Figure 6B, the enhanced ubiquitination of C/EBPa protein also
disappeared during NSC606985 treatment. Furthermore, GFP-
tagged PKCd-CF or its empty vector pEGFP-N1 was transfected
into HEK293T cells together with C/EBPa and His6-tagged
ubiquitin constructs, followed by immunoprecipitation of C/EBPa
protein and blots for the ubiquitin and C/EBPa proteins. The
results demonstrated that only co-transfection of C/EBPa and
His6-ubiquitin induced a lower degree of ubiquitination of C/
EBPa protein (lane 1, Figure 6C), which was significantly
enhanced by MG132 treatment (lane 2, Figure 6C). Similar to
that seen in NSC606985-treated NB4 cells (Figure 6A/B), addition
of GFP-PKCd-CF also increased the ubiquitinated C/EBPa
protein in the presence of co-transfection of C/EBPa and
ubiquitin (lane 3, Figure 6C). It should be pointed out that,
although the transfected C/EBPa protein could also be destructed
by the ectopically expressed PKCd-CF and rescued by MG132
(top panel, Figure 6C), co-administration of MG132 did not
significantly increase the ubiquitinated C/EBPa protein induced
by co-transfection of PKCd-CF and ubiquitin (lane 3, Figure 6C)
or NSC606985 treatment (Figure 6A). All these results suggested
that the activated PKCd mediated the enhanced ubiquitination of
C/EBPa protein under NSC606985 treatment.
Silencing of C/EBPa expression by siRNAs enhances while
inducible expression of C/EBPa inhibits NSC606985/
etoposide-induced apoptosis in leukemic cells
Finally, three pairs of siRNAs (C1–3) against C/EBPa were
designed and transfected into U937 cells. With selection by G418,
C2 and C3 siRNAs but not C1 siRNA significantly inhibited C/
EBPa protein expression, compared with negative control
(Figure 7A). The suppression of C/EBPa expression by C2 and
Figure 5. Proteasomal pathway involves increased C/EBPa protein degradation induced by proteolytically activated PKCd. (A) U937
cells were treated with or without 50 nM NSC606985 for 36 hours in the presence and absence of 10 mM of MG132 for 5 hours, 1 mM of epoxomicin
for 5 hours or 1 mM bortezomib for 12 hours respectively before harvest. C/EBPa, Dcaspase-3 and PKCd proteins were detected by Western blots with
b-actin as an internal control. (B) After pre-treatment with or without 25 nM of NSC606985 or 0.5 mM of etoposide for 12 hours, NB4 cells were
incubated with 10 mM MG132 for 30 min prior to the addition of 10 mg/ml CHX for the indicated hours. C/EBPa protein was detected with b-actin as
a loading control.
doi:10.1371/journal.pone.0006552.g005
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side-induced activation of caspase-3 (Figure S6) and apoptosis, the
latter being determined by the percentages of sub-G1 cells
(Figure 7B), annexin-V
+ cells (Figure 7C) as well as cell morphology
(Figure S7). On the other hand, an inducible C/EBPa-expressing
cell line (U937
C/EBPa) was generated using myeloid leukemic
U937T cells as described above. U937
empty cell line with
transfection of empty vector was used as a control. As can be
visualized in Figure 8A, C/EBPa protein was significantly induced
at 6 days after tetracycline withdrawal in U937
C/EBPa cells. Hence,
we treated U937
empty and U937
C/EBPa cells with NSC606985 or
etoposide when tetracycline was removed for 8 days. The results
showed that the inducible expression of C/EBPa partially inhibited
NSC606985/etoposide-induced caspase-3 action (Figure S8) and
apoptosis to a statistic degree (Figure 8B/C and Figure S8). These
results supported the anti-apoptotic role of C/EBPa. Additionally,
conditional expression of C/EBPa protein failed to alter expressions
ofapoptosis-relatedBcl-2,Bak,BaxandMcl-1genesinU937
C/EBPa
cells (Figure 8D), and the suppression of C/EBPa expression by
siRNAs also failed to alter Bcl-2 protein level (Figure 7A).
Discussion
Previously, a variety of DNA-damaging agents such as UV,
etoposide and bleomycin were shown to induce C/EBPa
expression in keratinocytes, but not in HepG2, NRK or NIH
3T3 cells, indicating that the induction of C/EBPa by DNA
damage is dependent upon cell context [36]. Although we also
found that both NSC606985 and etoposide appeared to induce a
rapid but transitory elevation of CEBPA expression in U937 but
not NB4 cells, all apoptosis-inducing agents tested here induced a
profound down-regulation of C/EBPa protein in leukemic cell
lines NB4 and U937 as well as in primary leukemic cells when
apoptosis occurred. Further investigation showed that NSC606985
and etoposide significantly shortened the half-life of C/EBPa
protein and reduced expression of CEBPA mRNA and CEBPA
promoter-driven luciferase reporter assay, suggesting that inhibi-
tion of transcription and induction of protein degradation of C/
EBPa contributed to down-regulation of C/EBPa protein during
apoptosis induction.
Inhibition of caspase-3 by Z-DEVD-fmk failed to rescue
NSC606985-reduced C/EBPa protein, and the purified recombi-
nant active fragment of caspase-3 did not cleave C/EBPa protein in
vitro, indicating that activated caspase-3 does not contribute to
PKCd-induced instability of C/EBPa protein during apoptosis. It is
believed that PKCd is a substrate for the apoptosis-critical
executioner caspase-3, which cleaves PKCd to a 41 kDa
catalytically active fragment [19,37]. Vice versa, the ability of
PKCd activation to enhance DNA-damaging agents such as
cisplatin-induced apoptosis was correlated with their ability to
enhance caspase-3 activation, and rottlerin inhibits cisplatin or
NSC606985-induced activation of caspase-3 [14,38,39], proposing
that PKCd also acts upstream of caspase-3 to regulate its activation.
Therefore, there is a feedback loop between PKCd and caspase-3 to
promote apoptosis [18,40,41]. Of note, it remains not to be
completely clear how DNA damage activates PKCd. Although it
was proposed that PKCd may regulate its own cleavage in response
to apoptotic stimuli [38], recently we used quantitative proteomic
analysistoidentifythedifferentiallyexpressedproteinsbeforePKCd
activation induced by NSC606985 in U937 cells. As a result, a total
of 33 proteins were found to be dysregulated in this situation and we
proposed that the downregulation of N-myc downstream regulated
gene 1 (NDRG1) is involved in proteolytic activation of PKCd
during apoptosis induction [39].
Next, we investigated whether the down-regulation of C/EBPa
protein is mediated by proteolytically activated PKCd. Our results
Figure 6. Ectopic expression of active form of PKCd facilitates ubiquitination of C/EBPa protein. (A) NB4 cells were treated with or
without 25 nM of NSC606985 for 12 hours and/or 10 mM MG132 for 5 hours before harvest. (B) After pretreatment for 2 hours in the presence or
absence of 1 mM of rottlerin, NB4 cells were treated with or without 25 nM of NSC606985 for additional 12 hours. (C) HEK293T cells were transfected
with C/EBPa, ubiquitin and other plasmids as indicated for 24 hours. Then, cells were treated with or without 20 mM MG132 for 5 hours before
harvest. Cell lysates were co-immunoprecipitated with anti-C/EBPa antibody, and precipitates or total lysate (input) were detected by western blots
for GFP, PKCd, C/EBPa and ubiquitin.
doi:10.1371/journal.pone.0006552.g006
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PLoS ONE | www.plosone.org 7 August 2009 | Volume 4 | Issue 8 | e6552Figure 7. Silencing of C/EBPa expression by siRNAs enhances NSC606985/etoposide-induced apoptosis in leukemic cells. (A) U937
cells were stably transfected with siRNA C1–3 against C/EBPa or negative control vector (NC), and C/EBPa and Bcl-2 proteins were blotted with b-
actin as a loading control. (B) U937 cells with stable transfections of C1-C3 or NC were treated with 2 mM etoposide or 200 nM NSC606985 for
24 hours, and apoptotic sub-G1 cells% were determined on flow cytometry. (C) U937 cells with stable transfections of C1-C3 or NC were treated with
2 mM etoposide or 200 nM NSC606985 for 36 hours, and annexin-V
+ cells% were determined on flow cytometry. The values represent mean6S.D. of
triplicates in an independent experiment, which was repeated more than three times with the same results. The symbols * and # represent P,0.01
and ,0.05 compared with NC cells with the corresponding treatment.
doi:10.1371/journal.pone.0006552.g007
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transfection of DN-PKCd partially rescured C/EBPa protein but
not its mRNA level upon NSC606985 treatment, suggesting that
the activated PKCd protein contributes to the increased
degradation of C/EBPa protein but not to the reduced
transcription of CEBPA by DNA-damaging agents. This notion
is also supported by the fact that transfected expression of the
PKCd-CF reduces C/EBPa protein but not its mRNA.
In accordance with previous reports [14,42,43], overexpression
of the PKCd-CF is sufficient to induce apoptosis, and proteolytic
activation of PKCd exerts a critical role in NSC606985-induced
apoptosis at least in AML cells. However, mechanisms of PKCd-
mediated apoptosis are controversial. PKCd is a mobile enzyme,
and its intracellular distribution is altered upon activation. This is
one way to reach the appropriate targets in order to elicit its
biological responses. One of the most important questions is how
and where PKCd transduces its apoptotic signals. It appears that
PKCd can act at several locations for apoptosis induction,
including the plasma membrane, mitochondria and nucleus.
Previously, we showed that NSC606985-induced PKCd cleavage
simultaneously occurs in the cytoplasm and nuclei of both NB4
and U937 cells [14]. In spite of the subcellular localization, it
remains to be illustrated what are the downstream targets of PKCd
for apoptosis induction. In response to DNA damage, as reported
[44], catalytic fragment of PKCd can phosphorylate and inactivate
DNA-dependent protein kinase, resulting in further cell death.
PKCd can also phosphorylate p73b, a member of the p53 family
[45]. Lamin B and phospholipid scramblase 3 were also proposed
to be substrates of PKCd and could contribute to apoptosis
[46,47]. Thus, PKCd can contribute to apoptosis by phosphor-
ylating different targets that are localized in the nucleus, plasma
membrane or mitochondria. However, our immunoprecipitation
experiment did not support the C/EBPa-PKCd interaction and
the activated PKCd did not appear to directly induce phosphor-
ylation of C/EBPa protein (data not shown). On the other hand,
the NSC606985-induced decrease of C/EBPa protein was
Figure 8. Inducible C/EBPa expression inhibits NSC606985/etoposide-induced apoptosis in leukemic cells. (A) U937
empty and
U937
C/EBPa cells were incubated for days as indicated after removal of tetracycline (Tet), and C/EBPa protein was detected with b-actin as a loading
control. (B-C) After pre-incubation in the absence of tetracycline for 8 days, U937
empty and U937
C/EBPa cells were treated with 200 nM NSC606985 or
2 mM etoposide for 24 hours, and the percentages of apoptotic sub-G1 cells (B) and annexin-V
+ cells (C) were determined on flow cytometry. The
values represent mean6S.D. of triplicates in an independent experiment, which was repeated more than three times with the same results. The
symbol * represents P,0.01 compared with U937
empty cells with the corresponding treatment. (D) U937
empty and U937
C/EBPa cells were incubated for
days as indicated after removal of tetracycline and the indicated proteins were detected with b-actin as a loading control.
doi:10.1371/journal.pone.0006552.g008
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132, epoxomicin and bortezomib. Of great importance,
NSC606985 and ectopic expression of PKCd-CF significantly
increased ubiquitination of endogenously and ectopically ex-
pressed C/EBPa protein, while rottlerin significantly inhibited the
enhanced ubiquitination of endogenously expressed C/EBPa
protein during NSC606985 treatment. Although the effect of the
forced expression of DN-PKCd on ubiquitination of C/EBPa
protein remains to be determined, all these results suggested that
activated PKCd mediates proteasome-dependent degradation of
C/EBPa protein, which is involved the enhanced degradation of
C/EBPa protein upon apoptosis induction. In fact, a recent report
showed that the von Hippel-Lindau tumor-suppressor protein, a
ubiquitin-ligase (E3) directing proteasome-dependent degradation
of targeted proteins, interacts directly with the catalytic domain of
PKCd in cells [48], and PKCd does mediate proteasome-
dependent degradation of certain proteins such as mitogen-
activated protein kinase phosphatase-1 and p21
cip1 [49,50]. By the
way, we also found that activated PKCd could alter the subcellular
localization of C/EBPa protein (data not shown), which might be
related to the degradation of C/EBPa protein.
It remains to be investigated how CEBPA mRNA was reduced
during apoptosis induction. The actinomycin-inhibiting test
showed that NSC606985 or etoposide treatment failed to alter
the stability of CEBPA mRNA (data not shown), suggesting that
the transcription of CEBPA may be regulated, which could be
supported by the CEBPA promoter driven luciferase reporter
assay. As reported [51–53], the consensus recognition sequences of
some apoptosis-related transcription factors such as sp1, myc/max
and AP2a are present in the promoter region of CEBPA gene.
Therefore, the down-regulation of CEBPA during apoptosis
induction may also be associated with these factors. Additionally,
the auto-activation function of C/EBPa protein has been reported
[54]. Thus, we cannot exclude the possibility that the decrease of
CEBPA mRNA is due to the reduced C/EBPa protein although
the decrease of C/EBPa protein but not its mRNA was partially
rescued by rottlerin and the expression of PKCd-CF also reduced
C/EBPa protein but not its mRNA.
The inhibition of caspase-3 by its specific inhibitor did not
completely inhibit PKCd activation-related apoptosis, suggesting
that caspase-3-independent mechanism(s) also contributes to the
event [14,18,42,55]. The fact that C/EBPa protein was one of the
down-stream effectors of the activated PKCd during apoptosis
induction pushed us to explore its possible role in apoptotic event.
Here we showed that inhibition of C/EBPa expression enhanced,
while its over-expression inhibited, DNA-damaging agents-induced
apoptosis, which could be shown by annexin-V
+ cells%, especially
bysub-G1 cells%andapoptosis-related morphologicanalysis.These
results demonstrated that the modulation of C/EBPa expression
contributes, at least partially, to the activation of PKCd-mediated
apoptosis. It was proposed that C/EBPa induces the expression of
the anti-apoptotic Bcl-2 gene [11]. However, this notion could not
be confirmed in this work. Similarly, conditional expression of C/
EBPa protein did not alter other apoptosis-related genes, including
Bak, Bax and Mcl-1. Therefore, molecular mechanisms of anti-
apoptotic effect of C/EBPa remain to be explored.
Taken together, our results demonstrated that C/EBPa
expression is down-regulated in apoptotic leukemic cells partially
through induction of protein degradation, the latter involving
proteolytically activated PKCd-enhanced ubiquitination of C/
EBPa protein. Furthermore, C/EBPa exerts a role in chemother-
apeutic drugs-induced apoptosis. These results would shed novel
sights for understanding mechanisms of PKCd-related apoptosis
and functions of C/EBPa between differentiation and apoptosis.
Materials and Methods
Cell treatment and apoptosis assay
Leukemic cell lines, including NB4 [56] and U937, were grown
in RPMI-1640 medium (Sigma-Aldrich, St Louis, MO) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS, Gibco
BRL, Gaithersburg, ML) in 5% CO2/95% air humidified
atmosphere at 37uC. U937T cells, which were kindly provided
by Dr. Tenen D.G. at the Harvard Medical School (Boston, MA)
[27], are U937 cells stably transfected with a pUHD-tTA under
the control of a tetracycline-inducible promoter. U937T cells were
cultured in RPMI-1640 medium supplemented with 1 mg/ml
tetracycline (Sigma-Aldrich) and 0.5 mg/ml puromycin (Sigma-
Aldrich) with 10% FBS. For apoptosis induction, about
2610
5 cells/ml were initially seeded and incubated with indicated
concentrations of NSC606985 [kindly provided by National
Cancer Institute Anticancer Drug Screen standard agent database
and dissolved in double distilled water (ddH2O) as a 1 mM stock
solution], etoposide [BIOMOL, Plymouth, PA, dissolved in
dimethyl sulfoxide (DMSO) as 20 mM stock solution], doxorubi-
cin (BIOMOL, dissolved in ddH2O as 20 mM stock solution) or
As2O3 (Sigma-Aldrich), in the presence or absence of rottlerin
(BIOMOL) prepared in ethanol as 1 mM stock solution or Z-
DEVD-fluoromethyl ketone (Z-DEVD-fmk, BD Biosciences, San
Diego, CA) dissolved in DMSO. MG132 and epoxomicin
(BIOMOL) were dissolved in DMSO or bortezomib (Millennium
Predictive Medicine Inc., Cambridge, MA) in phosphate-buffered
saline (PBS) and stored at 220uC until usage. For induction of
apoptosis by UV irradiation, cells were exposed to a germicidal
lamp providing predominantly 254-nm UV-C light (Philips TUV
G30T8 30 W bulb). To assess apoptosis, cell morphology, cell
viability, annexin V with and without PI staining and sub-G1 cells
as previously described [14] as well as activity of caspase-3 were
measured. The activity of caspase-3 was measured by caspase-3
assay kit colorimetric (sigma-aldrich) according to the manufac-
turer’s instruction.
Primary cells from patients and ethics statement
Mononuclear cells in BM, which were obtained from one case
of M3-subtyped and one case of M5-subtyped AML patients
according to French-American-British classification, were aspirat-
ed by Ficoll-Paque liquid and suspended in RPMI-1640 medium
with 10% FBS. This study was conducted according to the
principles expressed in the Declaration of Helsinki. The study was
approved by the Ethic Committee of Shanghai Jiao Tong
University School of Medicine. All patients provided written
consent for the collection of samples and subsequent analysis.
Plasmids
Full-length C/EBPa cDNA and PKCd-CF (the catalytic
fragment of PKCd) were amplified by PCR from pCMV-
SPORT-C/EBPa plasmid (kindly provided by Dr Gombart AF
in Cedars-Sinai Medical Center, Los Angeles, CA) and pEGFP-
PKCd-CF (kindly provided by Dr Reyland ME in School of
Dentistry, University of Colorado Health Sciences Center,
Denver, CO), respectively, and were subcloned into pTRE2hyg
expression vector (BD clontech, Palo Alto, CA) to form the
pTRE2hyg-C/EBPa or pTRE2hyg-PKCd-CF plasmid. Human
C/EBPa or human AML1-ETO cDNA amplified from U937-A/
E 9/14/18 cells by RT-PCR [57] was also subcloned into pGEX-
4T3 vector (Amersham Biosciences, Buckinghamshire, England)
to construct GST-tagged C/EBPa or AML1-ETO-expressing
vector. To obtain His-tagged active caspase-3, human caspase-3
cDNA lacking N-terminal 28 amino acid residues was amplified
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CA) vector following the protocol of Lee KK et al [58]. Plasmid
construct PMT107 (vector for His6-Ubiquitin expression) was a
kind gift from Dr. Ying Jin in institute of Health Science, SIBS
(Shanghai, CHINA) [59]. DN-PKCd was amplified by PCR from
pCDNA3-PKC-DNd plasmid [a gift from Dr.Jae-Won Soh (Inha
University, Incheon, Korea) [60] and was subcloned into a
puromycin murine stem cell provirus (pMscv-puro) expression
vector (Clontech) to form the pMscv-puro-Flag-DN-PKCd
plasmid. The sequences of all cDNA inserts of plasmids were
confirmed by sequencing.
Luciferase assay
pRL-SV40 vector and CEBPA promotor-driven luciferase
plasmid, which was a pGL3-basic-luciferase reporter vector
(Promega, Madison, WI) cloned with a 3.1 kb DNA fragment
consisting the 59 flanking region (21t o23000) and the first 103 bp
ofthefirstexonofthe humanCEBPAgene(GenBankNM_004364),
were transferred into NB4 cells by electroporation using Gene-
Pulser II (Bio-Rad, Hercules, CA) at 150 V and 960 mFo rU 9 3 7
cells by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA)
following the manufacturer’s protocol. Twenty-four hours after
transfection, NB4 and U937 cells were treated with or without
NSC606985 or etoposide for hours as indicated. The cell luciferase
activity was measured by the Dual-Luciferase Assay system
(Promega) according to the manufacturer’s instructions. The
measured luciferase activity was normalized for pRL-SV40 Renilla
luciferase activity for each sample, and luciferase activity was
expressedasfoldsoverthecorrespondinguntreatedcellsrespectively.
Establishment of stable transformants
To generate U937
C/EBPa or U937
PKCd-CF stable transformants,
1610
7 U937T cells were washed in RPMI 1640 medium and
resuspended in 0.2 ml of Isceve’s Modified Dulbecco’s medium
without FBS. Twenty micrograms of pTRE2hyg C/EBPa or
pTRE2hyg PKCd-CF plasmid in 20 ml ddH2O was transferred to
electroporation cuvette with a 0.4 cm gap (Bio-Rad, Hercules,
CA). Electroporation was performed using a Gene-Pulser II (Bio-
Rad) at 170 V and 960 mF. The samples were then transferred to
complete RPMI-1640 medium. Twenty-four hours later, 1 mg/ml
tetracycline, 0.5 mg/ml puromycin and 500 mg/ml hygromycin B
(Clontech) were added. Cells were then incubated at 37uCi n5 %
CO2. Positive polyclonal populations were identified based on
Western blot after tetracycline removal, and were maintained in
RPMI-1640 medium supplemented with 10% FBS, and 1 mg
tetracycline, 0.5 mg/ml puromycin and 500 mg/ml hygromycin B.
For retroviruses transfection, viral supernatants were produced in
HEK293T cells cotransfected with the pMSCV-puro or pMscv-
puro-Flag-PKC-DNd constructs and packaging vectors pEQPAM
(containing gag-pol, provided by Dr. Lishan Su in UNC Chapel
Hill, USA) and VSV-G (Clontech). Viral supernatants were
collected 48 hours after transfection, filter-sterilized, and stored at
280uC. Before using 6-well plate was coated with 10 mg/ml
Fibronectin for more than 4 hours at 37uC, and the viral
supernatants with final concentration of 4 mg/ml Polybrene were
added to U937 cells 2610
5 cells/well in 6-well plate. Forty eight
hours later, selection with puromycin (0.7 mg/ml) was started.
Positive polyclonal populations were identified based on Western
blot for Flag-DN-PKCd.
siRNA design and transfection
Three pairs of complementary siRNA oligonucleotides against
C/EBPa (C1–3) were synthesized by Invitrogen (Shanghai,
China), annealed and ligated into pSilencer 3.1-H1-neo vector
(Ambion, Austin, TX). Their target sequences for C/EBPa were
59-GAACAGCAACGA GTACCGG-39 for C1, 59-CCTTGTG-
CCTTGGAAATGC-39 for C2 and 59-CACTTGTATCTGGCC
TCTG-39 for C3. These siRNA vectors and the negative control
pSilencer neo vector (Ambion) were respectively transfected into
U937 cells using the Gene-Pulser II (Bio-Rad) with square-wave
electroporation of 2 pulses, 0.18 kV, 25 ms, 1 Hz. Forty-eight
hours later, 800 mg/ml G418 (Calbiochem) was added to the
medium and the stable transformants were selected by testing for
C/EBPa protein.
Purification of recombinant caspase-3 and in vitro
proteolysis of C/EBPa protein
His-tagged caspase-3 protein was expressed in bacteria BL21
(DE3) by induction with 1 mM isopropylthiogalactopyranoside
(IPTG) at 30uC,and was purified byaffinity chromatographyonNi-
NTA-agarose (Qiagen). The GST-C/EBPa or GST-AML1-ETO
wasexpressedinBL21byinductionwithIPTGat28uCand purified
using Bulk and RediPack GST Purification Modules (Amersham
Biosciences). Purified GST-C/EBPa or GST-AML1-ETO protein
was incubated with purified recombinant his-tagged active fragment
of caspase-3 in 100 mM HEPES (pH 7.2) containing 10 mM
dithiothreitol and 10% (v/v) glycerol at 25uCf o r1 8 0m i n .T h e
reaction was stopped by the addition of an equal volume of SDS-
PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis)
sample buffer and was then subjected to Western blot.
RT-PCR
Total cellular RNA was extracted by TRIzol reagent (Invitro-
gen), followed by treatment with RNase-free DNase (Promega).
RT was performed with a cDNA synthesis kit according to the
manufacturer’s instructions (Applied Biosystem, Forster City, CA).
For real-time quantitative RT-PCR, the following specific
oligonucleotide primers were used for C/EBPa (sense, 59-
GAATCTCCTAGTCCTGGCTC-39, antisense, 59-GATGAGA-
ACAGCAACGAGTAC-39 ) with 18S as an internal control
(sense, 59-AGGCCCTGTAATTGGAATGAGTC-39, antisense,
59- GCTCCCAAGATCCAACTACGAG-39). Real-time RT-
PCR was performed and data were analyzed as reported
previously [61].
Cycloheximide inhibition test
NB4 cells were pretreated with 25 nM NSC606985 or 0.5 mM
etoposide for 12 hours. Thereafter, cells were further incubated
with 10 mg/ml cycloheximide (CHX, Sigma-Aldrich) as indicated
in the figure legend. C/EBPa protein was tested by Western blots
using b-actin as loading controls.
Ubiquitination detection and western blot
To detect the ubiquitination of C/EBPa protein, cell lysates were
immediately boiled in 1% SDS for 15 min followed by dilution with
the lysis buffer (50 mM HEPES, 50 mM NaCl, 0.1% Tween-20,
10% glycerol, 20 mM sodium pyrophosphate, 1 mM dithiothreitol,
plus protease inhibitors) to 0.1% SDS. Then, the lysates were
incubated with anti-C/EBPa antibody (sc-61, Santa Cruz Biotech,
Santa Cruz, CA) and protein A-agarose (Santa Cruz) and rocked
overnight at 4uC. The complexes were centrifuged at 1,200 g and
washed three times with ice-cold lysis buffer. Immunoprecipitated
proteins and protein extracts were equally loaded on 10–12% SDS-
polyacrylamide gel, and transferred to nitrocellulose membrane
(Amersham Bioscience). The blots were stained with 0.2% Ponceau
Sredtoensureequalproteinloading.Afterblockingwith5%nonfat
milk in PBS, the membranes were incubated with antibodies against
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Bcl-2, p53, Mcl-1, Bax (Santa Cruz), Bak (Sigma-Aldrich), active
caspase-3 [cleaved caspase-3 (Asp175)], ubiquitin (Cell Signaling,
Beverly, MA) and b-actin (Calbiochem), followed by horseradish
perioxidase (HRP)-linked secondary antibodies (Cell Signaling).
Detection was performed using a chemiluminescence phototope-
HRP kit (Dako, Carpinteria, CA). When necessary, signal intensity
of C/EBPa protein was normalized against b-actin as internal
control using GS-800 calibrated imaging density meter (Bio-Rad),
and folds of changes were expressed compared with untreated cells.
Statistical analysis
All experiments were repeated at least for three times with the
same results. The Student’s t-test was used to compare the
difference between two different groups. A value of p,0.05 was
considered to be statistically significant.
Supporting Information
Text S1 Supplemental Materials
Found at: doi:10.1371/journal.pone.0006552.s001 (0.03 MB
DOC)
Figure S1 NSC606985 induces apoptosis of NB4 and U937
cells. NB4 and U937 cells were treated respectively with 25 nM
and 50 nM of NSC606985 for hours as indicated, the percentages
of annexin-V
+ cells with and without PI staining (A) and apoptotic
sub-G1 cells (B, in the gate of line scale) were determined on flow
cytometry, and cell morphology was examined after Wright’s
staining (C). The values represent mean6S.D. of triplicate in an
independent experiment, which was repeated more than three
times with the same results.
Found at: doi:10.1371/journal.pone.0006552.s002 (7.82 MB
DOC)
Figure S2 Etoposide induces apoptosis of NB4 and U937 cells.
NB4 and U937 cells were treated respectively with 0.5 mM and
1 mM of etoposide for hours as indicated, the percentages of
annexin-V
+ cells with and without PI staining (A) and apoptotic
sub-G1 cells (B, in the gate of line scale) were determined on flow
cytometry, and cell morphology was examined after Wright’s
staining (C). The values represent mean6S.D. of triplicate in an
independent experiment, which was repeated more than three
times with the same results.
Found at: doi:10.1371/journal.pone.0006552.s003 (8.53 MB TIF)
Figure S3 Various apoptosis-inducing agents induce NB4 cell
apoptosis. NB4 cells were treated with 2 mMA s 2O3, 0.5 mM
doxorubicin or irradiated by 150J UV for hours as indicated, the
percentages of annexin-V
+ cells with and without PI staining (A)
and apoptotic sub-G1 cells(B, in the gate of line scale) were
determined on flow cytometry, and cell morphology was examined
after Wright’s staining (C). The values represent mean6S.D. of
triplicate in an independent experiment, which was repeated more
than three times with the same results.
Found at: doi:10.1371/journal.pone.0006552.s004 (4.03 MB TIF)
Figure S4 Effects of DN-PKCd expression on NSC606985
induced CEBPA transcription inhibition. U937
Flag-DN-PKCd and
U937
vehicle cells were treated with 50 nM NSC606985 for 36
hours. Then, the relative CEBPA mRNA was determined by real-
time quantitative RT-PCR. The columns represent means of
change folds of CEBPA mRNA against untreated cells, with the
bar as S.D. of three independent experiments.
Found at: doi:10.1371/journal.pone.0006552.s005 (1.53 MB TIF)
Figure S5 Effects of the proteasome inhibitors on the cell
viability in the absence and presence of NSC606985. U937 cells
were treated with (black column) or without (white column) 50 nM
NSC606985 for 36 hours, and MG132 (10 mM), epoxomicin
(1 mM) and bortezomib (1 mM) were added for 5, 5 and 12 hours
respectively before harvest with vehicle as control. Cell viability
(top panel) was measured by trypan-blue exclusion assay. Annexin-
V
+ cells% (bottom panel) was measured on flow cytometry. All
values represent mean6S.D. of triplicates in an independent
experiment. All the experiments were repeated more than three
times with the same results.
Found at: doi:10.1371/journal.pone.0006552.s006 (5.19 MB TIF)
Figure S6 Effects of suppression of C/EBPa expression by
siRNAs on NSC606985/etoposide-induced caspase-3 activation.
U937 cells with stable transfections of C1-C3 or NC were treated
with 2 mM etoposide or 200 nM NSC606985 for hours as
indicated, the caspase-3 activation was measured as described in
supplemental materials and methods. The values represent
mean6S.D. of triplicate in an independent experiment, which
was repeated more than three times with the same results. The
symbols * represent P,0.01 compared with NC cells with the
corresponding treatment.
Found at: doi:10.1371/journal.pone.0006552.s007 (2.27 MB TIF)
Figure S7 U937 cells with stable transfections of C1-C3 or NC
were treated with 2 mM etoposide or 200 nM NSC606985 for
hours as indicated, cell morphological features were examined
under microscope after Wright’s staining.
Found at: doi:10.1371/journal.pone.0006552.s008 (9.37 MB TIF)
Figure S8 After pre-incubation in the absence of tetracycline for
8 days, U937
empty and U937
C/EBPa cells were treated with
200 nM NSC606985 or 2 mM etoposide for hours as indicated,
cell morphological features were examined by microscope after
Wright’s staining of cells (A), and the caspase-3 activation was
measured as described in materials and methods (B). The values
represent mean6S.D. of triplicate in an independent experiment,
which was repeated more than three times with the same results.
Found at: doi:10.1371/journal.pone.0006552.s009 (8.09 MB TIF)
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